Kinetic and Binding Studies of Streptococcus pneumoniae Type 2 Isopentenyl Diphosphate:Dimethylallyl Diphosphate

Matthew Walter Janczak1, C Dale Poulter1

  • 1Department of Chemistry, University of Utah , 315 South 1400 East, Salt Lake City, Utah 84112, United States.

Biochemistry
|March 23, 2016
PubMed

Insights

Type 2 isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IDI-2) is a bacterial enzyme and potential antibacterial target. Its activity is modulated by flavin mononucleotide (FMN) reduction, with reaction kinetics influenced by oxygen levels and substrate binding.

Area of Science:

  • Biochemistry
  • Enzymology
  • Antimicrobial drug discovery

Background:

  • Type 2 isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IDI-2) synthesizes essential isoprenoid precursors.
  • IDI-2 is a non-human homolog and potential target for novel antibacterial agents.
  • The enzyme requires reduced flavin mononucleotide (FMNH2) for catalysis, forming an IDI-2·FMNH2·IPP complex.

Purpose of the Study:

  • To elucidate the kinetic mechanism of Streptococcus pneumoniae IDI-2.
  • To investigate the role of flavin mononucleotide (FMN) reduction in IDI-2 activity.
  • To explore the impact of aerobic and anaerobic conditions on enzyme kinetics.

Main Methods:

  • Enzyme kinetics assays using varying substrate and cofactor concentrations.
  • Stopped-flow spectrophotometry to monitor flavin reduction rates.
  • Comparative analysis of reaction rates under aerobic and anaerobic conditions.

Main Results:

  • IDI-2 follows a modified sequential ordered mechanism with FMN binding before IPP.
  • Aerobic conditions with NADH and IPP lead to sigmoidal kinetics with respect to FMN concentration.
  • Flavin reduction rates are significantly slower under aerobic conditions compared to anaerobic conditions or dithionite reduction.
  • A rate-limiting conformational change may occur during NADH-dependent flavin reduction in the presence of IPP.

Conclusions:

  • The catalytic mechanism of IDI-2 is sensitive to oxygen availability and substrate binding.
  • Understanding these kinetic properties is crucial for developing IDI-2 as an antibacterial target.
  • The observed sigmoidal kinetics suggest complex regulatory mechanisms potentially exploitable for drug design.

Related Concept Videos